Trivedi Maharshi, Meena Pinky, Tak Himangi, Dave Dipesh, Chandra Minu, Joshi Nitin, Panchal Harsha P, Gandhi Jahnavi
Pediatric Oncology, The Gujarat Cancer and Research Institute, Ahmedabad, IND.
Pediatrics, All India Institute of Medical Sciences, Rajkot, IND.
Cureus. 2025 May 22;17(5):e84650. doi: 10.7759/cureus.84650. eCollection 2025 May.
Epithelial ovarian neoplasms (EON) are uncommon in children and data is limited. We conducted this study to assess the clinical characteristics and outcomes of children and adolescents with EON. Children ≤18 years of age diagnosed with EON, between 1st January 2010 and 31st December 2022 were included for retrospective analysis. Clinical characteristics, treatment details, and outcomes were noted. One-hundred-sixteen patients were diagnosed with ovarian mass, and eight (0.07%) of them were EON. Median age was 17 years (range: 13-18 years). One (12.5%) patient had a family history of breast cancer. One (12.5%) had borderline serous cystadenocarcinoma, four (50%) had malignant serous, and three (37.5%) had malignant mucinous adenocarcinoma. One girl with borderline disease (stage Ia) was treated with surgery and is alive. Among seven patients with malignant EONs, two (28.6%), two (28.6%), two (28.6%), and one (14.2%) had stage Ia, II, IIIc, and Iva disease, respectively. Two (28.6%) patients underwent primary debulking surgery. Two patients (28.6%) received neoadjuvant chemotherapy (NACT) followed by interval debulking. Three (42.8%) patients received chemotherapy and did not undergo surgery because of stable/progressive disease. Two patients (25%) with stage Ia were alive without evidence of disease. One girl (12.5%) with stage IIb relapsed after primary treatment and succumbed to the disease. All three patients with stage IIIc and one with stage IVa had relapse/progression, and three patients succumbed to the disease. Malignant EONs require multimodality treatment. Advanced disease and serous tumors are associated with poor survival. With a mean (± standard deviation) follow-up of 56 ± 10 months, the three-year progression-free survival (PFS) and overall survival (OS) were 37.5%±17.1% and 70%±18.2%, respectively.
上皮性卵巢肿瘤(EON)在儿童中并不常见,相关数据有限。我们开展这项研究以评估患有EON的儿童和青少年的临床特征及预后情况。纳入2010年1月1日至2022年12月31日期间诊断为EON的18岁及以下儿童进行回顾性分析。记录临床特征、治疗细节及预后情况。116例患者被诊断为卵巢肿块,其中8例(0.07%)为EON。中位年龄为17岁(范围:13 - 18岁)。1例(12.5%)患者有乳腺癌家族史。1例(12.5%)患有交界性浆液性囊腺癌,4例(50%)患有恶性浆液性肿瘤,3例(37.5%)患有恶性黏液性腺癌。1例患有交界性疾病(Ia期)的女孩接受手术治疗后存活。在7例恶性EON患者中,分别有2例(28.6%)、2例(28.6%)、2例(28.6%)和1例(14.2%)患有Ia期、II期、IIIc期和IVa期疾病。2例(28.6%)患者接受了初次肿瘤细胞减灭术。2例患者(28.6%)接受了新辅助化疗(NACT),随后进行间隔性肿瘤细胞减灭术。3例(42.8%)患者接受化疗,因疾病稳定/进展未接受手术。2例Ia期患者(25%)存活且无疾病证据。1例IIb期女孩(12.5%)在初次治疗后复发并死于该疾病。所有3例IIIc期患者和1例IVa期患者均出现复发/进展,3例患者死于该疾病。恶性EON需要多模式治疗。晚期疾病和浆液性肿瘤与较差的生存率相关。平均(±标准差)随访56±10个月,三年无进展生存率(PFS)和总生存率(OS)分别为37.5%±17.1%和70%±18.2%。